NCT01953354终止2 期
A Prospective, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study of Trichuris Suis Ova Treatment in Left-sided Ulcerative Colitis and Its Effects on Mucosal Immune State and Microbiota
National Institute of Allergy and Infectious Diseases (NIAID)34 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2013年11月最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 16
- 试验地点
- 34
- 主要终点
- Percentage of Participants Who Achieved a Clinical Response at Week 12
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of trichuris suis ova (TSO) in ulcerative colitis (UC). We will look at how TSO affects the body's immune response and if there are related changes in participants' UC.
详细描述
The cause of UC, an inflammatory bowel disease (IBD), is not well understood. It is believed to be caused from an abnormal immune response to the normal bacteria that live in the gut (intestines and colon). This response acts as an "attack" on the healthy tissue of the bowel by a person's own immune cells which leads to disease.
It is well known that autoimmune diseases such as IBD, asthma, diabetes, and multiple sclerosis are more common in industrialized, well-developed countries with better sanitation and hygiene, as in the United States. These "cleaner" environments reduce exposure to germs and parasites naturally found in the environment. This reduced exposure may trigger responses in the body that make people more prone to diseases such as UC. People in non-industrialized countries and the tropics, where parasites are common, rarely develop these diseases. This observation has led researchers to want to better understand the relationship between the lack of natural bacteria in the gut and the onset of autoimmune diseases like as UC.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has provided written informed consent
- •Diagnosis of UC (newly diagnosed or established patients) as determined by medical history, endoscopic and histological confirmation with the proximal disease extent limited to the left colon (distal to the splenic flexure), and accessible by flexible sigmoidoscopy. Patients with left-sided disease and the presence of a periappendiceal red patch (limited cecal inflammation) will be eligible as long as there is no intervening evidence of colitis between the cecal base and the upper boundary of inflammation in the left colon.
- •Mayo score >/= 4, as scored at Screen 2
- •If taking the following medications at Screen 1, subjects must meet the following criteria:
- •Oral Corticosteroids: stable treatment for at least 4 weeks prior to Day 0 with a maximum dose equivalent to <\=15 mg/day of prednisone
- •Immunosuppressants (azathioprine (AZA) or 6-mercaptopurine (6-MP)): treatment for at least 12 weeks with a stable dose, not exceeding 2.5 mg/kg/day of AZA or 1.5 mg/kg/day of 6-MP, during the 4 weeks prior to Day 0
- •Aminosalicylates: stable oral doses up to 4.8 g/day for at least 4 weeks prior to Day 0.
排除标准
- •Subjects whose UC is anticipated to require surgical, endoscopic, or radiologic intervention during study participation
- •Uncontrolled GI bleeding
- •Subjects who have disease limited to the rectum (maximum disease extent of less than 15 cm)
- •Women who are pregnant, breast-feeding, or planning to become pregnant during the study. All women of childbearing potential must have a negative serum pregnancy test at Screen 2 prior to randomization of treatment.
- •Women of childbearing potential not using adequate birth control measures (e.g., total abstinence, oral contraceptives, intrauterine device, barrier method with spermicide, surgical sterilization, Depo-Provera, or hormonal implants).
- •Current or recent serious systemic disorder including clinically significant impairment in cardiac, pulmonary, liver, renal, endocrine, hematologic, or neurologic function, based on investigator discretion
- •Subjects currently receiving the following concomitant medications:
- •Prednisone or its equivalent at unstable doses or at doses exceeding 15 mg/day within 4 weeks prior to Day 0
- •Local steroids such as budesonide, Colifoam, or Predsol enemas within 2 weeks prior to Screen 2
- •Topical therapies, either mesalamine or steroids, taken within 2 weeks of Screen 2
- •Non-steroidal anti-inflammatory drugs (NSAIDs), Cyclooxygenase (COX)-2 inhibitors, or aspirin >100 mg/day within 2 weeks prior to Screen 2
- •Tumor necrosis factor (TNF)-alpha inhibitors including but not limited to infliximab (Remicade) or adalimumab (Humira) within 12 weeks of Day 0
- •Any biological agent within 12 weeks of Day 0
- •Metronidazole within 4 weeks of Day 0
- •Receipt of any investigational agent within the 12 weeks prior to Day 0
- •Antibacterial or oral antifungal agents within 4 weeks of Screen 2
- •Interferon (IFN) therapy
- •Anticoagulants
- •Methotrexate
- •Blood transfusion within the 12 weeks prior to Day 0
- •Presence of any of the following abnormal laboratory parameters at Screen 1:
- •Hemoglobin < 10.0 g/dL
- •White Blood Count (WBC) < 4,000 or > 20,000/L (equivalent to WBC < 4 or > 20 x109/L)
- •Platelets < 100,000 or > 800,000/L (equivalent to platelets < 100 or > 800 x109/L)
- •Total bilirubin > 1.5 × Upper limit of normal (ULN)
- •Alanine transaminase (ALT) > 2 × ULN
- •Aspartate transaminase (AST) > 2 × ULN
- •Alkaline phosphatase (ALK) > 1.5 × ULN
- •Gamma-glutamyl transferase (GGT) > 1.5 × ULN
- •Creatinine > 1.5 × ULN
- •History of drug or alcohol abuse within one year prior to Day 0
- •Inability to understand the nature and requirements of the study, or to comply with the study procedures or planned schedule of study visits
- •Evidence of infection with human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
- •Active infection with C. difficile, bacterial enteric pathogens, or pathogenic ova/parasites
- •History of malignancy within the last 5 years, except for resected basal or squamous cell carcinoma, treated cervical dysplasia, or treated in situ cervical cancer Grade I
- •History of colonic dysplasia
- •Any social or medical condition that, in the opinion of the investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
结局指标
主要结局
Percentage of Participants Who Achieved a Clinical Response at Week 12
时间窗: Week 12
Clinical response is defined as a reduction in the Mayo score of at least 3 points and at least a 30% reduction from Baseline, along with either a decrease from Baseline in the rectal bleeding subscore of more than 1 point or a rectal bleeding subscore of 0 or 1.
次要结局
- Percent of Participants With a Modified Clinical Response(From Day 0 through time of first clinical response or end of follow-up, whichever comes first, up to 12 Weeks)
- Percent of Participants With Increase in Diarrhea(From Day 0 through end of follow-up, up to 36 weeks)
- Time to Modified Clinical Response(From Baseline through the day that modified clinical response is reached. Week 16 is the last visit that the modified Mayo score is assessed.)
- Percent of Participants With Healed Colonic Mucosa at Week 12(Week 12)
- Percent of Participants Who Achieved Remission at Week 12(Week 12)
- Percent of Participants With Colonoscopic Evidence of Visible Worm(From Day 0 through end of follow-up, up to 36 weeks)
- Percent of Participants With Increase in Concurrent Ulcerative Colitis (UC) Medications or New Rescue Medications Added(From Day 0 through Week 16)
研究者
研究点 (34)
Loading locations...
相似试验
进行中（未招募）
1 期
Treatment with eggs of pig whipworm for patients with rheumatoid arthritis, who are insufficiently treated with methotrexateMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid arthritisEUCTR2011-006344-71-DEImmanuel Krankenhaus Berlin50
尚未招募
1 期
Trichuris suis ova (TSO) as an additional therapy for rheumatoid arthritis patients with insufficient response to methotrexate. A prospective, double-blind, randomized, controlled monocenter studyOther rheumatoid arthritisM06M05Seropositive rheumatoid arthritisDRKS00005323Immanuel Krankenhaus Berlin50
已完成
2 期
Trichuris Suis Ova Therapy for Relapsing Multiple Sclerosis - a Safety StudyRelapsing Multiple SclerosisNCT01006941Rigshospitalet, Denmark10
已完成
1 期
Trichuris Suis Ova in Peanut and Tree Nut AllergyFood AllergyNCT01070498Beth Israel Deaconess Medical Center18
终止
1 期
Efficacy Study of Trichuris Suis Ova to Treat Chronic Plaque PsoriasisPsoriasisNCT01948271Tufts Medical Center3